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rely and toxic Shock Syndrome: 
A technological Health crisis
Sharra L. Vostral, PhD
Department of Gender and Women’s Studies and Department of History, University of 
Illinois Urbana-Champaign, Champaign, Illinois
This essay examines factors leading to the identification of Toxic Shock Syndrome with the
bacteria Staphylococcus aureus in 1978 and the specific role of Rely tampons in generat-
ing a technologically rooted health crisis. The concept biologically incompatible technology
is offered to explain the relationship between constituent bacteria, women’s menstrual cy-
cles, and a reactive technology that converged to create the ideal environment for the S. au-
reus bacteria to live and flourish in some women. The complicated and reactive relationship
of the Rely tampon to emergent disease, corporate interests, public health, and injury law
reveals the dangers of naturalizing technologies.
introduction
Since the early 1980s, health advo-
cates, marketers, scientists, and physicians
have taught menstruating women that the
use of a tampon may cause Toxic Shock
Syndrome (TSS†). For the most part, we
have a general understanding that tampons
are to blame for TSS. One college student
said that in her microbiology class, she
learned “if you leave a tampon in too long,
you can get Toxic Shock Syndrome.” This
message has been so well distributed and
internalized that this misleading statement
is understood as scientific fact. However,
despite  the  good  intentions  to  protect
women’s  health,  the  message  about  the
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misunderstanding. Tampons alone do not
cause  TSS.  Specifically,  the  bacterium
Staphylococcus  aureus (S.  aureus)  is  re-
sponsible for TSS, and its role and compli-
cated  relationship  to  the  tampon  have
vanished from the message.  
In an effort to simplify warnings, pro-
tect women’s lives, and stem a potential epi-
demic  at  one  moment  during  the  early
1980s, the irrefutable link between tampon
use and possible death served a necessary
purpose. Yet, the simplification not only
overlooks facts, it has perpetuated misinfor-
mation, instilled unnecessary fear in women,
and placed the responsibility upon women
to police their bodies to prevent TSS. The
historical memory about the production of
synthetic (rather than cotton) tampons and
the identification of a disease has been re-
duced to warning labels and informational
pamphlets, making tampons culpable for a
deadly bacterial infection while simultane-
ously universalizing all women to be at risk. 
This essay examines factors leading to
the identification of Toxic Shock Syndrome
with the bacteria Staphylococcus aureus in
1978 and the specific role of Rely tampons
in generating a technologically rooted health
crisis. I develop the concept of biologically
incompatible technology to explain the rela-
tionship  between  constituent  bacteria,
women’s menstrual cycles, and a reactive
technology that converged to create the ideal
environment for the S. aureus bacteria to
live and flourish in some women. Identify-
ing and naming the condition associated
with  the  symptoms  presented  by  these
women proved to be one underlying chal-
lenge. Linking these symptoms not only to a
bacterium but also to a new technology —
the Rely tampon produced by Proctor &
Gamble  —  created  a  second  problem.
Lastly, warning women about the danger of
using tampons constituted a third element of
this health crisis. Each phase utilized science
in a different way to manipulate action. How
the science was used and by whom is also
an underlying theme in this story of the tech-
nologically rooted health crisis of TSS and
tampons.
BAckground: toxic SHock
Syndrome
In order to better understand the histor-
ical origins of tampon-related TSS, is it use-
ful  to  begin  with  the  currently  accepted
clinical case definition of TSS put forth in
February 1980 and established by the Cen-
ters for Disease Control (CDC). According
to the CDC, the clinical case of Toxic Shock
Syndrome included a fever of 102 degrees
or more, rash, desquamation (flaking, peel-
ing skin), and hypotension (drop in blood
pressure,  dizziness).  It  also  included  the
broad  category  of  “multisystem  involve-
ment,” which encompasses three or more of
the following: gastrointestinal (vomiting, di-
arrhea), muscular pain (creatine phosphoki-
nase levels twice that of normal), mucous
membranes (enlarged blood vessels of the
eye, throat, or vagina), renal dysfunction
(blood urea nitrogen or creatinine twice that
of normal without the presence of a urinary
tract infection), liver dysfunction (serums
twice that of normal), blood abnormalities
(platelets less than 100,000/mm3), and cen-
tral nervous system issues (disorientation).
Lastly, negative results ruling out diseases
such as measles and Rocky Mountain spot-
ted fever and negative throat, blood, and
cerebrospinal fluid cultures eliminated dis-
eases with similar symptoms.  The CDC also
indicated that a TSS diagnosis of “probable”
included five of the six categories, while
“confirmed” included six of the six cate-
gories [1]. 
A condition named in 1978 and further
defined in 1980, Toxic Shock Syndrome had
been identified across the population, in-
cluding both adult men and children. How-
ever, its etiology took a unique course with
the overwhelming majority of cases at the
time linked to tampon-using women. The
particular strain of Staphylococcus aureus
responsible for tampon-related Toxic Shock
Syndrome is more specifically referred to as
Toxic Shock Syndrome Toxin-1 (TSST-1).
Though  TSS  seemed  to  come  out  of
nowhere, the bacterium Staphylococcus au-
reus is not new. Named in 1884 for its yel-
low-hued  clusters,  S.  aureus produces  a
variety of ailments from rashes, pimples,
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soning [2]. It is responsible for a variety of
diseases, and about 20 percent of the general
population carries S. aureus on the skin and
many more carry it in the nose. S. aureus has
different relatives, some of whom produce
enterotoxins, harmful and toxic proteins spe-
cific to cells in the intestine and responsible
for food poisoning. Others create exotoxins,
toxic materials secreted and released by the
bacteria that may travel throughout a per-
son’s body. More recently, methicillin-resis-
tant  Staphylococcus  aureus (MRSA),
currently known as the “super bug” con-
tracted in hospital-like settings, has gained
notoriety.
An emergent tAmpon 
tecHnology: rely
The link between TSS and tampons was
not intuitive. Tampons had become a trusted
and normalized technology in upwards of 70
percent of women’s hygiene routines [3].
What  had  changed  were  the  materials,
whose composition shifted from cotton to
synthetic  materials  [4].  Companies  often
sought cheaper ingredients, and rayon — de-
rived from wood pulp and combined with
cotton — served to be a cost-effective and
efficient absorptive material in some tam-
pons. As new polymer technology emerged
during the 1960s, companies began to add
more  synthetic  materials,  such  as  poly-
achrylates, to tampons. Most major brands
utilized synthetics to varying degree, in-
cluding  Playtax,  Tampax,  and  Kotex.
Though the components changed, tampon
shape and design did not alter substantially
[5]. 
A newcomer to the tampon market,
Proctor & Gamble needed a radically su-
perior product to lure consumers from tra-
ditional brands. It aimed to revolutionize
the  market  when  it  introduced  Rely,
named presumably because it was more
“reliable” than other products. According
to the packaging, women could also rely
on it to manage mental strife because “it
even absorbs the worry” [6]. Researchers
there championed a tampon composed of
polyester foam cubes and chips of car-
boxymethylcellulose, an edible thickening
agent used in puddings and ice cream and
known as “grass” — recognized as safe
because it passes through the body with-
out decomposing [7]. Encapsulated within
a polyester teabag-like pouch, the tampon
was unlike any other. According to Martin
Cannon, Associate  Director  of  Product
Development at Proctor & Gamble, the
biggest problem that the researchers iden-
tified  with  available  tampons  was  the
issue of “bypass,” the tendency for men-
strual fluid to flow past the tampon, which
resulted in leaks. This was due, in part, to
the shape of the tampon that usually ex-
panded lengthwise, without conforming to
the  contours  of  the  vaginal  cavity  [8].
Thus, the design intention of the new tam-
pon  was  good  because  it  worked  with
vaginal physiology by expanding width-
wise as well.
During the design process, corporate
scientists followed generally accepted stan-
dards of product safety, which in retrospect
proved to be shortsighted. This was in part
due to changes in regulations, which at the
time seemed to be fortuitous for Proctor &
Gamble. In May 1976, new regulatory poli-
cies emerged in the Food & Drug Adminis-
tration  (FDA)  to  ensure  the  safety  of
medical  devices,  known  as  the  Federal
Food,  Drug  and  Cosmetic Act  (FDCA).
The act regulated labeling and branding,
with an eye toward protecting consumers
from misleading claims. In addition, the
Medical Device Amendments (MDA) set
further protections by requiring that com-
panies seek “pre-market approval” for new
devices from the FDA [9]. Re-categorized,
tampons and sanitary napkins were now no
longer cosmetics but medical devices, just
like  toothbrushes  and  pacemakers.  The
Rely tampon, however, was first test-mar-
keted in Fort Wayne, Indiana, in 1974, pre-
dating the new 1976 FDA regulations that
spared it from testing [10]. As such, Proc-
tor & Gamble was not bound by federal law
to produce scientific evidence concerning
Rely’s  safety  because  it  was  “grandfa-
thered” in.
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as 1975 with sample packets of Rely, and
the tactic proved wildly successful. Rely
was officially introduced for sale across
the country in August 1978, with market-
ing efforts escalating each year. The num-
ber of packets — with four tampons per
box — distributed through the mail was
impressive  and  aggressive:  45  million
samples distributed, with the April 1980
campaign alone numbering 16.8 million
samples [11]. In an interview with Lisa,
she recalled receiving these samples and
saving them for a special occasion. As she
explained:  “It  was  1980,  and  Styx  was
playing at the Cow Palace in Oakland. We
took the BART from San Jose (or rather
Fremont, near where we lived) and antici-
pated little bathroom access” at the arena
so  the  tampons  offered  a  big  “conve-
nience” to her instead of waiting in the pre-
dictably  long  lines  at  the  women’s
restroom. It was the first time she had used
Rely, and the tampon worked amazingly
well. But, she said, “I remember removing
that Rely tampon after getting home late at
night and wondering whether I had lost my
virginity, that thing had gotten so huge. I
stopped using them after that because of
being too grossed out.” 
As it turned out, there was more to fear
than a perpetually expanding tampon. The
unique components, instead of being inert
as Proctor & Gamble scientists assumed,
possessed what I call reactive traits that set
into motion a complex chain of events that
few  understand  well  to  this  day.  Philip
Tierno, a politically active microbiologist,
contends in his 2004 book The Secret Life of
Germs that there were three major factors
promoting S. aureus to present as TSS. First
were  the  synthetic  components  of  Rely,
consisting of foam cubes and the gelling
agent carboxymethylcellulose encased in a
polyester  pouch.  The  gelled  car-
boxymethylcellulose in essence acted like
agar in a petri dish, providing a viscous
medium on which the bacteria could grow.
Along with this, the foam cubes offered in-
creased surface area for proliferation. Sec-
ond was the changing pH of the vagina
during menstruation, to about 7.4. The opti-
mal pH for S. aureus to trigger TSS is 7, or
neutral.  The  relatively  acidic,  non-men-
strual vagina measures a pH of about 4.2,
which keeps S. aureus well in check. Tierno
also hypothesized that a tampon introduces
both carbon dioxide and oxygen into the
usually anaerobic vagina, thus the gases of-
fered an abundant food source to S. aureus.
Finally, the pyrogenic toxins produced by S.
aureus induced fever in humans. This fever
of about 102 degrees proved to be the per-
fect temperature for S. aureus to reproduce
and thus create further deadly toxins [12].
An additional factor was a woman’s age;
many adult and older women had built up
immunity to some forms of S. aureus, while
young  women  and  teenagers  were  more
susceptible without a developed immune re-
sponse to the pathogen. In some cases, TSS
presented as mild, flu-like symptoms, while
in others the toxins released literally sent
the person into shock. 
Though Tierno’s work is readily acces-
sible to lay audiences, many other scientists
and research groups have examined TSS and
TSS-1 and published results in various aca-
demic journals that detail conflicting results
and no definitive answers.1 These multiple
variables intensified the health crisis. There
was no scientifically agreed upon under-
standing of how tampons specifically trig-
gered TSS; the bodies of only some and not
all  women  harbored  S.  aureus that  then
ramped into overproduction. S. aureus might
be part of the normal ecology of a woman’s
body, be a passing germ, or successfully
eliminated from her body by her immune
system. Not all of these variables were rec-
ognized at the time, and even as some char-
acteristics emerged, they were difficult to
translate into a health warning. And, though
other  tampons  also  triggered  TSS,  Rely
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1It is not the goal of this essay to list all the scientists who have researched S. aureus or TSS and ad-
judicate their scientific accuracy, but to shed light on how scientific thinking influenced policy decisions
that ultimately affected women’s perceptions about their bodies and how each should manage her own
period.shouldered the brunt of the responsibility for
the outbreak.
conceptuAlizing BodieS, 
BActeriA, And injury
At root, the tampon, once a culturally
risky technology, had been embraced by a
majority of women and many manufactur-
ers by the late 20th century. So ubiquitous
was the technology that catastrophic dys-
function seemed improbable. In part, this
was also due to a prevailing notion of the
body as an independent agent. As historian
Linda Nash has pointed out, the modern
conception of the body relies upon a bacte-
riological notion of disease as existing out-
side an otherwise healthful person. She calls
for reclaiming the ecological body, one more
porous and situated with and within a land-
scape and environment, often polluted with
industrial toxins also now found in human
bodies [13]. I am suggesting an even broader
framework of bodily ecology to look inward
to include an ecology complete with bacter-
ial constituents. I argue that this model must
take into account the internal ecologies, for
though the body is also subject to its exter-
nal environment, it is situated among condi-
tions created by not only bacterium, but
viruses, fungi, and the like. Some also refer
to this ecosystem as a personal microbiome,
and the NIH has embarked on a project to
characterize  these  communities  with  the
Human Microbiome Project (HMP).
This means looking to bacterium with a
different perspective and using different lan-
guage to explain its behavior and activity.
We have come to understand bacteria as
having some generalizable traits. There is
“symbiosis,” when organisms often live and
interact together [14]. More specifically, this
relationship may be mutual (benefiting both
organisms), commensal (benefiting one but
not harming the other), and parasitic (living
at the expense of the other) [15]. Heather
Paxon refers to political debates about bac-
teria, and particularly food pasteurization, as
micropolitics [16]. Extending her discussion
of politics, I suggest that claiming bacteria
as constituents eliminates the need to evalu-
ate them as good or bad. Some bacteria are
simply part and parcel of being human, and
considering them constituents affords them
a bit of recognition in the larger body politic.
Labeling bacteria as constituent also avoids
the problematic constructions of the “host”
body, in which a universal male bears the
burden of feeding the greedy pests. Never
mind that the body is not a gendered female
hostess; the body simply becomes the site
for  unwelcome,  ungrateful,  and  usually
harmful guests. Constituents also demand a
degree of representation, unlike the bacteria
that form “colonies” that rebel against the
master body and take on the pejorative role
of an invader [17]. According to this model,
the body is not a holistic ecosystem, but a
primary empire exerting dominance, power,
and control. 
This naturalized understanding of the
body as empire falls far short in conceptual-
izing how multiple life forms interact with
technologies in and of the body. It may be
that there are technologies that are funda-
mentally compatible with muscle tissue, but
not the indigenous bacteria living quite well
on the skin. I suggest the category biologi-
cally incompatible technology to help inter-
rogate  those  innovations  that  are  not
primarily deadly or harmful to humans but
have potential to produce other biological
harm through their use.2With this analytical
move, I suggest that it is not enough for sci-
entists and designers to consider just the
human body, but a core question in the de-
sign  of  medical  and  bodily  technologies
must also be “how will this object interact
with bacterial constituents?” Furthermore,
we should ask how emergent nanotechnol-
ogy will interact with bacterial constituents.
A premise of my analysis is to consider the
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2In the appendix to “Biotechnology in the Twentieth Century,” Robert Bud lists evolving terms for biotech-
nology, in which Craig & Boelter introduced biologically compatible technology in 1947. I, therefore, am
suggesting the opposite of this, which must be understood in terms of multiple life forms and biologies
including bacterium. See Bud, Robert, “Biotechnology in the Twentieth Century.” Social Studies of Sci-
ence 21.3 (August 1991): 415-457.two non-human entities of tampon and bac-
teria as necessary and vital cofactors of a
medical and technological drama [18,19,20].
In the case of TSS, this powerful relation-
ship between technology and bacterium was
not just overlooked (since this would imply
willful disregard) but worse, unimagined as
a possibility.3
As a technology capable of inducing
TSS, Rely tampons did not fit the mold for
usual measures of product injury. It differed
because it possessed the potential to precip-
itate a reactive consequence, but not neces-
sarily direct injury from the object per se.
The uneven injuries were difficult to track
medically and from a legal, compensatory
model as well. This is not a surprise. The
likes  of  lead  poisoning,  asbestosis  and
mesothelioma, and other environmental pol-
lutants are constant reminders of damage
caused  by  human-created  products
[21,22,23]. Sarah Lochlann Jain has theo-
rized about the social and economic conse-
quences of human wounding resulting from
manufactured goods. She argues that injury
is not merely an unfortunate accident, but in-
tegral and assumed within consumption and,
therefore, capitalism itself. She suggests “in-
jury law demonstrates the recursive way in
which design issues also materialize and nat-
uralize sets of injuries as visible and com-
pensable or invisible and non-compensable”
[24]. Jain looks at examples such as the Ford
Pinto, cigarettes, and keyboards, to name a
few. In these types of cases, the relationship
of technology to injury can be interpreted as
causal.
The resulting injury brought about by
Rely, however, was complicated because the
causal model did not fully account for rela-
tional injury. In and of itself, Rely was not
defective. It was not composed of toxic ma-
terials causing direct harm or triggering can-
cerous  growths. As  a  medical  device,  it
seemed inert, and Rely did not directly cause
TSS. The injury incurred is better under-
stood, I argue, through a reactive model.
Once moistened and lodged in a vaginal
canal, Rely held the strong potential to in-
teract with bacterium that may be present as
constituent  communities  within  some
women’s bodies. Since makers presumed it
to be inert, the leap to the reactivity of the
technology seemed far-fetched.4Yet, the live
bacteria and synthetic tampon energetically
interacted and were co-factors in producing
illness. As Jain points out, design flaws may
materialize as visible requiring compensa-
tion or remain invisible and go unrecog-
nized.  It  is  exactly  the  invisibility  of  a
reactive gendered technology in the form of
a tampon and injury manifesting in women’s
bodies identified as Toxic Shock Syndrome
that contributed to this health crisis.
reSeArcH And teSting
How this injury played out varied con-
siderably. Much of my research is based
upon Kehm v. Proctor & Gamble, the 1982
liability case that took place in the federal
courthouse in Cedar Rapids, Iowa, in which
the family of Patricia Kehm sued Proctor &
Gamble upon her death from TSS linked to
the use of Rely tampons. It was the first suc-
cessful case to sue Proctor & Gamble and
win  a  favorable  judgment  concerning  a
wrongful death, made particularly troubling
since she died on September 6, 1980, just
days before the products were pulled from
market shelves on September 22. Proctor &
Gamble was ordered to pay $300,000 in
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3James Todd adds, “It should have been obvious that the group of young women with ‘vaginitis’ were
of menstruating age and, in fact, three of our original patients, in retrospect, were menstruating at the
onset of their illness, but we missed completely the possibility of any connection with tampon use.”
See James K. Todd, “Toxic Shock Syndrome—Scientific Uncertainty and the Public Media.” Pediatrics
67.6 (June 1981): 921-923. p. 922.
4Recognition of indirect harm is gaining traction. Recently, the EPA announced that it will set limits on
perchlorate in drinking water. According to physician and CNN chief medical correspondent Sanjay
Gupta, “it’s the first time we’ve ever regulated a chemical not because of what it does directly to you,
but because it has an impact on iodine uptake that might affect your child down the road.” CNN
Health [Internet]. “EPA to set limit on chemicals in drinking water.” (accessed Feb 2, 2011). Available
from: http://www.cnn.com/2011/HEALTH/02/02/epa.water.chemical/index.html.compensatory damages, and the lawyer for
the case, Tom Riley, said it was “the highest
verdict in Iowa’s history for the death of a
housewife” [25].
The court exhibits and trial transcript
offer insight about the product development
of  Rely,  how  the  company  managed  the
phone  calls  of  concerned  women  who
thought they must be experiencing an aller-
gic reaction to tampons, and the drama sci-
entists  felt  in  identifying  an  unnamed
epidemic.  The  trial  revealed  that  indeed
Proctor & Gamble had spent a good deal of
time and effort testing the tampon, though
researchers missed the greater picture of
bacterial interactions with technology.
In fact, according to Martin Cannon in
product development at Proctor & Gamble,
scientists conducted more than enough test-
ing, and furthermore, the company had gar-
nered its solid reputation through meticulous
research protocol [26,27]. The individual
components  comprising  Rely  were  each
scrutinized to ensure the sanitary nature of
the product itself. By 1979, new require-
ments concerning protocol and data collec-
tion were required by the FDA, and Proctor
& Gamble moved forward by meeting crite-
ria in advance of these laws. Specifically,
Proctor & Gamble conducted clinical trials
in which 1,332 women participated in vari-
ous  studies,  which  in  scientific  parlance
amounted to “730 woman years of experi-
ence with Rely tampons,” according to the
company [28]. Minor ulcerations compara-
ble to that of Tampax were reported to the
FDA, and the results of both acute and long-
term toxicity tests — based upon 1 full week
of use and another spanning more than 2
years — in animals proved negative [29].
Scientists determined carcinogenic and ter-
atogenic potential of the new product by
fashioning pledgets — tiny tampons — for
mice to wear [30]. Of course, mice do not
menstruate, so there can be no valid results
related to interactions with menstrual fluids.
Nonetheless, the results yielded data that
convinced corporate leaders as well as the
FDA that the products were not cancerous.
Scientists also assayed changes in mi-
croflora of the vagina, a process that proved
more  difficult.  As  Cannon  described  it:
“What we find is that the microflora of the
vagina . . . it just changes, changes for an in-
dividual woman, and it changes in spite of
what product habits that, you know, we were
able to observe.” His is not an unusual reac-
tion to the vagina as a vexing site for con-
trol.  The  history  of  medicine  and
gynecology is rife with examples to subdue
women’s  reproductive  health,  including
pregnancy, fertility, and menstruation. In this
case, women’s bodies were unable to con-
form to the dictates of the lab to remain
fixed; for the scientists, there were just too
many variables related to the fluctuating,
permanent, and transient microorganisms to
isolate. Thus, lab conditions were different
than environmental conditions, and the sci-
entists were not required by any regulating
body, whether internal or external, to con-
duct such tests [31].
However,  not  all  was  rosy.  By  July
1980, one of the junior engineers, referred
to by only his last name, Dzialo, in memos,
wrote to R.L. Stone at Proctor & Gamble,
expressing some frustrations about the re-
search process. Apparently, around 1978,
during the so-called “absorbency wars” trig-
gered by competitors’ offerings, work had
begun on “Rely N,” the next generation of
Rely tampons. As Dzialo put it: “With all
major brands offering comparable product
performance, Rely’s marketing objective of
category  leadership  is  seriously  jeopard-
ized.” One reason for this, he felt, was a poor
understanding of the vagina and its fluids.
“[I]t is clear than an inadequate understand-
ing of menstrual fluid characteristics and of
the functional anatomy of the vagina has
complicated an already difficult task. An im-
proved understanding of both areas would
significantly reduce the need for a trial by
error mode of operation” [32]. Here, Dzialo
voices what Harry Collins and Trevor Pinch
describe as “experimenter’s regress;” that is,
the difficulty for “a test to have an unam-
biguous outcome because one can never be
sure whether the test has been properly con-
ducted until one knows what the correct out-
come ought to be” [33]. In many ways, the
scientific testing had no way to measure the
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unknowable at that time.
nAming A new Syndrome
The case of TSS was not easily identi-
fied in tampon-using women because re-
searchers had not thought to look for it.
All-cotton tampons had not posed such a
threat, and no one had ever heard of TSS.
Thus, there were two unknown variables
needing identification: the role of the syn-
thetic tampon and the labeling of a new dis-
ease.  While  Proctor  &  Gamble  made
preparations in Cincinnati for distribution of
this new product, a physician in Denver
began tracing the similarities of symptoms
in some of his patients. It was only in 1978
that “the toxic shock syndrome” was named
by  pediatricians  James  Todd  and  Mark
Fishaut working in the Department of Pedi-
atrics at the Children’s Hospital of Denver
and University School of Medicine with
their colleagues Frank Kapral in the Depart-
ment of Medical Microbiology at Ohio State
University and Thomas Welsh in the De-
partment of Pediatrics, Herkimer Memorial
Hospital in New York [34]. As historian of
medicine Charles Rosenberg argues, it is
only after a set of symptoms is named as a
disease or ailment that social constructions
of behaviors, treatments, and expectations of
patients and clinicians can be associated
with it [35]. Thus, according to Todd and the
other researchers, children were constructed
as the patients. As described in The Lancet,
symptoms  included  high  fever,  rash,
headache, vomiting, acute renal failure, and
even severe shock in seven boys and girls
between the ages of 8 and 17 between 1975
and 1977. The link that Todd, the principle
investigator, was able to make between the
children was that the infection derived from
phage-group-I Staphylococcus aureus. He
referred to this as “a unique new syndrome”
affecting older children, different from scar-
let fever or Rocky Mountain spotted fever
that share some similar traits [34]. It was
also framed within the category of new dis-
eases such as Kawasaki’s disease or Reye’s
syndrome that affect children. Such a small
sampling was nowhere near an epidemic,
more like a blip in infectious diseases seen
in children. 
Yet, Todd’s article in The Lancet be-
came the authoritative academic work on
TSS because this was the only published
piece  to  outline  specific  symptoms  and
name this Staph-related infection as a syn-
drome. How this health crisis in children
could be linked to tampon use was not obvi-
ous, and it is the very origins of these initial
cases that caused many to dismiss any sort
of association with Rely. What could be the
possible relation between young children,
and even men, with the number of women
who were exhibiting scarlet fever-like symp-
toms? Luckily, Jeffrey Davis, the new State
Epidemiologist and Chief of the Section of
Acute  and  Communicable  Disease  Epi-
demiology  at  the  Wisconsin  Division  of
Health, became familiar with TSS in 1978
while completing a pediatrics residency and
pediatric infectious diseases fellowship at
Duke University, before the publication of
Todd’s article. When colleagues at the Uni-
versity of Wisconsin School of Medicine
contacted him in late 1979 with questions
about  three  patients  exhibiting  unusual
symptoms, Davis suggested that the cases
might be TSS [36]. He began investigating
commonalities among the women by asking
questions  about  grocery  purchases  that
might have linked them through food-borne
illness; travel and locale pointing toward re-
gional infections; and sex partners suggest-
ing  sexually  transmitted  infections.  In
addition, Davis remembered from his med-
ical training that often “menstrual history is
overlooked” [37]. He believed that it was
“more than a coincidence” that each con-
tracted her illness at the onset of the men-
strual period.  
By early 1980, his surveillance of four
other Madison hospitals revealed four more
cases. Upon learning of these new cases,
Davis took the proactive step of mailing a
report on January 31, 1980, to “3,500 in-
ternists, pediatricians and family practice
physician licenses in Wisconsin” concerning
the state of TSS, outlining surveillance pro-
cedures for the disease, and importantly, es-
454 Vostral: Rely and toxic shock syndrometablishing protocol for specimen collection.
In essence, Davis positioned physicians in
Wisconsin to be on the forefront of inter-
vention concerning TSS outbreaks, wher-
ever and however they might occur. This
proved to be a critical act. Davis, well-con-
nected to other university physicians and de-
partments of health, began receiving calls of
self-reported cases of TSS, questions from
practitioners, and requests for collaboration
with the Centers for Disease Control (CDC).
At the CDC, Kathy Shands, an Epidemic In-
telligence Service (EIS) officer in the Spe-
cial Pathogens Branch, requested input from
researchers and public health officials, in-
cluding Davis, to define the criteria of TSS.
Though the medical team outlined physical
symptoms and manifestations, the circum-
scribed definition carried political conse-
quences because numerous infected women
fell outside the strict boundaries. Many ar-
gued, and continue to do so, that the less se-
vere presentation of symptoms should be
included within the terms of the definition,
since it results in illness from TSS [38].
With such a specific set of criteria in
mind, researchers in different hubs began
to track outbreaks and define patterns of in-
fection. To summarize, there were a few
prominent studies linked to state-level de-
partments of health corroborating evidence,
sharing results, and exchanging informa-
tion. These included the Wisconsin Study, a
case control study emerging from interest
in Davis’s original mailing, during the win-
ter and early spring of 1980, the results of
which were formally published in the New
England Journal of Medicine. During the
summer of 1980, the CDC also conducted
CDC-1 and later CDC-2. This small study
matched 52 cases with 52 controls, with all
of the cases using tampons at the onset of
menstruation.  CDC-2,  conducted  during
the fall of that year, examined methodology
of “recall accuracy” and the size of the tam-
pons used, as well as the brand. It was
CDC-2  that  implicated  Rely,  citing  its
prevalence in relation to TSS and women’s
menstrual hygiene practices. So impressed
with the results, the research team pub-
lished preliminary findings in the Septem-
ber 19, 1980, edition of the CDC’s Mor-
bidity Mortality Weekly Report (MMWR).  
Using the benchmark date of September
19, the Tri-State TSS study coming out of
Minnesota, Iowa, and Wisconsin carefully
examined cases, brands, and absorbency as
related to TSS. The researchers found that
the absorbency of the tampon or the wearing
of Rely “were the only variables that signif-
icantly increased the relative risk of TSS.”
Furthermore, the study directly implicated
Rely, stating that “the rise associated with
Rely was greater than that predicted by ab-
sorbency  alone,  suggesting  that  chemical
composition of tampons was an important
factor” [39]. To offer a broader comparative
historical perspective concerning the extent
of the problem, microbiologist Philip Tierno
surmised that “of the more than 2,200 cases
reported to the CDC though June 1983, 90
percent were associated with women who
were menstruating at the time they became
ill. Most of these women were young, and 99
percent were using tampons” [40].
policy mAking: deciSionS And
inconcluSive Science
Problems  concerning  synthetic  tam-
pons, especially Rely, moved from the realm
of speculation to public health fact during
the spring and summer of 1980. Discontent
from  consumers  grew  from  whispers  to
more angry complaints directed at Proctor
& Gamble. As far as Proctor & Gamble was
concerned,  its  scientists  had  conducted
sound research, and there was no reason to
question the integrity of the new product. In
a memo from Gordon Hassing, a director of
product safety, to Peter Morris in research
and development on June 24, 1980, Hassing
assured him, “[t]hus far, there is no direct
evidence for the causal involvement of tam-
pons in TSS. The etiology of TSS is un-
known but is likely to involve an infectious
agent.” In many ways, he was correct. It was
not a causal relationship, as understood in
usual risk and injury cases. However, it was
a cofactor in that it caused a reactive en-
counter with S. aureus, precipitating illness
in some women. Though he believed Rely
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might come from the media. He continued
by saying that “the potential for adverse
publicity for tampons as a product category
remains high, particularly if the CDC data
are made public irresponsibly. Strategically,
we can only help to keep any publicity from
being irresponsible.” By positioning Rely as
“part of the pack,” Hassing aimed to address
the TSS-tampon link as just that: associated
with a category as a whole and not a partic-
ular brand [41]. This tactic contradicted ear-
lier  marketing  with  its  focus  on  the
difference between Rely and other tampons.
The connection was crucial for the sale of
the tampon, and Hassing noted: “Keep this
problem only theoretically associated with
the category. This is extremely important be-
cause of the unique construction of Rely and
its very high marketing profile.” As a fol-
low-up to this deflection strategy just a few
days later on June 27, 1980, interdepart-
mental correspondence from area managers
flatly ordered representatives to control their
comments by stating: “You should not initi-
ate discussion of this subject” [42].
Managers at Proctor & Gamble grew
more concerned. The CDC had been keep-
ing all the affected companies apprised of
data and results coming from its studies.
Proctor & Gamble, however, wanted to con-
duct its own research to verify the findings
of the CDC. At first, researchers at the com-
pany requested to see the interviews and raw
data sets from the CDC, but it refused, citing
patient confidentiality. This would become
a contentious issue; in defense cases after
the product was discontinued, Proctor &
Gamble later accused the CDC of bad sci-
ence because it sought out sick individuals
and not a broad sampling [43]. Lawyers also
sought to subpoena records from the CDC
in order to obtain the names of women in-
terviewed during the CDC’s investigations,
purportedly to exonerate tampons as the cul-
prit of TSS [44]. The CDC countered that it
was in the business of epidemic prevention,
thus chasing disease was a crucial matter of
public health policy. Proctor & Gamble in-
terpreted this as a political solution and not
a scientific one, especially since policy de-
cisions were being based upon self-reported
cases to the CDC [45].
In order to bypass this disciplinary and
ethical squabble, researchers at Proctor &
Gamble exercised a new tactic: Track down
women who called the company complaining
of sickness but later recovered, and talk to
them more specifically about their health with
an eye toward gaining access to their medical
records, which presumably would more ac-
curately reflect a diagnosis of TSS by a cre-
dentialed physician. According to Roscoe
Owen Carter, the PhD chemist in charge of
paper products development and, therefore,
Rely, the self-reporting of TSS to doctors and
the CDC was sketchy at best, with cases not
meeting all of the criteria for the clinical def-
inition. He believed “the only way that you
could make a decision as to whether this
might have been toxic shock syndrome was
to get to the physician, talk with him, and then
actually see the medical records, go through
these medical records” [46]. 
Company officials used this aggressive
approach with Karen Swartzentruber and
her daughter from Washington, Indiana, who
purchased  Rely  tampons  from  the  local
Kmart. Swartzentruber complained to the
company on July 25, 1980, that her teenage
daughter was hospitalized with a Staph in-
fection and her doctor believed the cause of
it was Rely. By July 31, Carter called her
physician, Dr. Calder, who was quite forth-
coming about the teen’s symptoms, ranging
from high fever and muscle pain to diarrhea.
However, Calder withheld her name from
Proctor & Gamble. This was of no concern
to  Proctor  &  Gamble,  because  members
from Carter’s division spoke to the Kmart
store manager, who previously divulged the
identity of both Calder and Swartzentruber.
Under the guise of collecting medical evi-
dence, strategists at Proctor & Gamble fla-
grantly  violated  patient  confidentiality,
abetted no less by the family physician and
Kmart store manager [47]. Strategists and
managers at Proctor & Gamble seemed to
want it both ways: to invoke the need for
proper procedures by the CDC but violate
customary  patient/doctor  confidentiality
when it favored the company.
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as if Rely were safe, but evidence against
Rely mounted by September 1980. In an in-
terview, Nancy Buc, lawyer to the general
counsel at the FDA, recalled that she in-
formed the general counsel at Proctor &
Gamble that if the company was unwilling
to enter into a consent agreement and with-
draw the product, she was prepared to bring
it to court for violating the imminent hazard
injunction under the Medical Device Amend-
ments of the Federal Food, Drug and Cos-
metic Act, and she would do it personally.
According to Buc, it was clear that some-
thing was going on with Rely, but what ex-
actly it was remained uncertain. She felt her
job was to negotiate, as she put it, “sensible”
terms to remove the product from shelves
and have Proctor & Gamble comply with the
demands of warning the public about this
health threat. In this regard, Proctor & Gam-
ble  was  lucky.  Among  discussions  with
chain-of-command leadership, Buc recalled
that Secretary of Health & Human Services
Patricia Harris, cabinet member to President
Jimmy  Carter,  suggested  implementing  a
total ban upon all tampons. This seemed ex-
treme to Buc and reflected what Washington
Post staff writer Victor Cohn characterized
as a prevailing attitude among women, that
they “have become accustomed to the con-
venience of tampons, and giving up familiar
brands because of a slight chance of devel-
oping toxic shock syndrome seems almost as
preposterous as walking to avoid the danger
of car accidents” [3]. It was not Buc’s job to
determine the origin of the problem, but to
act to protect women and let them keep their
tampons, too.
The health crisis of tampon-related TSS
is inextricably linked to research and devel-
opment practices at Proctor & Gamble, the
science of epidemiology, the legal catego-
rization of tampons as medical devices, and
feminist notions of the right to a safe and hy-
gienic menstrual period. In addition, the re-
lationship of TSS to tampons reveals an
important triad of a woman’s body to bacte-
ria to technology to consider when design-
ing and developing new biotechnologies.
This case demonstrates the importance of
understanding the relationship of technolo-
gies to constituent bacterial communities in
women’s  bodies  and  thinking  beyond  a
causal model to a reactive model. The com-
plicated and reactive relationship of the Rely
tampon to emergent disease, corporate in-
terests, public health, and injury law reveals
the dangers of naturalizing technologies.
With growing reliance upon artificial joints
and implanted medical devices, the study
and framework of biologically incompatible
technologies, as read through Toxic Shock
Syndrome and tampons, offers a means to
re-evaluate safety and injury in relation to
all of our bodily ecologies.
concluSion
Though  Rely  was  the  focus  of  this
essay, all tampons were implicated, though
those with synthetic components and higher
absorbency seemed more amenable to S. au-
reus.  Recommendations  to  use  low-ab-
sorbency, cotton tampons seem sound, yet
do not entirely prevent an infection. The
only way to really prevent TSST-1 is to
avoid S. aureus altogether. At the current
moment, there is no standardized recom-
mendation to run a bacterial culture to see if
S. aureus is a permanent constituent vaginal
bacterium  for  a  particular  woman.  The
shortcoming of this is that S. aureus may be
permanent or transient and require follow-
up testing to make such a determination.
Though this is more commonly undertaken
before surgery to manage MRSA, it is not
currently a viable practice to test women’s
vaginas. Regardless of the viability of such
a procedure, for those women who perma-
nently harbor S. aureus, the knowledge of
this would be quite useful in making in-
formed decisions about their menstrual hy-
giene  choices.  For  those  women  with
transient S. aureus, the recommendations are
less clear. In this case, manufacturers rely
upon informed women knowing the signs
and symptoms of TSS, which are decep-
tively similar to the common cold and diffi-
cult  to  discern  as  life  threatening.
Researchers are also unsettled by the possi-
bility  of TSST-1  and  MRSA  exchanging
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prospect for tampon-using women [48].
This cultural and technological history
of tampon-related TSS is complicated, and
from this brief narrative presented here, it is
clear that historians, researchers, and clini-
cians must provide a more nuanced inter-
pretation of the disease and disease process.
We all must be more knowledgeable about
what TSS is and is not and have a better un-
derstanding of what it means to use tech-
nologies inside the body.
This is a story as much about technol-
ogy as it is a bacterium and assumptions
drawn based upon limited information to
users and non-users of technology. Though
pamphlets inserted into boxes are supposed
to explain all this, they often seem more
about liability instead of risk. It is exactly
the type of risk that needs further explana-
tion. TSS is rare, and more importantly, S.
aureus has preferred conditions in which it is
more likely to flourish, and this is with a
synthetic, super absorbent tampon. Overall,
the important message is to understand the
multiple variables involved and that tam-
pons  and  constituent  bacteria  are  active
agents within the human body.
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